5 SLE Patients See Disease Remission With CAR T-cell Therapy | Lupus News Today
No systemic lupus erythematosus patient receiving the CAR T-cell therapy infusion relapsed, all remained in remission for up to 17 months.| Lupus News Today
No systemic lupus erythematosus patient receiving the CAR T-cell therapy infusion relapsed, all remained in remission for up to 17 months.| Lupus News Today
A self-administered, under-the-skin injection version of AstraZeneca’s Saphnelo (anifrolumab-fnia) was effective for reducing disease severity in adults with systemic lupus erythematosus (SLE), according to results from an interim analysis of a Phase 3 clinical trial. “Today’s news takes us one step closer in making the clinically meaningful benefits of Saphnelo accessible for more patients with […] The post Trial testing under-the-skin Saphnelo in SLE hits main goal appeared first on...| Lupus News Today – The Web's Daily Resource for Lupus News
The FDA has granted fast track status to ADI-001, Adicet Bio’s CAR T-cell therapy for treatment-resistant systemic lupus erythematosus (SLE).| Lupus News Today
